First-Quarter 2021 Results and Highlights: Consolidated revenue increased 9% to $116 million Clinical Services revenue increased 4% to $96 million Pharma Services revenue increased 46% to $19 million Completed
NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter
ACCESSWIRE
First-Quarter 2021 Results and Highlights:
Consolidated revenue increased 9% to $116 million
Clinical Services revenue increased 4% to $96 million
Pharma Services revenue increased 46% to $19 million
Completed the acquisition of Trapelo Health in April
FORT MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the
Company
), a leading provider of cancer-focused genetics testing services, today announced its first-quarter results for the period ended March 31, 2021.
Mark W. Mallon, the Company s CEO said I couldn t be more excited to be joining NeoGenomics at such a pivotal time in the Company s history. Trends in the business are strong and we are positioned well to take market share as we emerge from the pandemic. Today s announced acquisition of Inivata along with the completion of the acquisition of Trapelo Health in April are significant milestones on our journey t